← Back to Search

Rehabilitation Program for Spastic Ataxia

N/A

Recruiting

Research Sponsored by Université du Québec à Chicoutimi

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have a confirmed genetic diagnosis of ARSACS or SPG7

Be able to maintain standing position and to transfer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 consecutives days, 2 times

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to evaluate the effectiveness of a 12-week rehabilitation program called IMPACT on individuals with spastic ataxias. Spastic ataxias are diseases that cause walking difficulties and balance issues

Who is the study for?

This trial is for individuals with spastic ataxias, a group of conditions causing walking difficulties and balance problems. Participants should have these symptoms but not be undergoing any other specific treatments for them during the trial.

What is being tested?

The study tests a 12-week supervised rehabilitation program called IMPACT, designed to reduce disease severity in spastic ataxias compared to usual care. It also examines how well this program can be implemented in clinical settings and its cost-effectiveness.

What are the potential side effects?

Since IMPACT is a non-pharmacological rehab program focusing on exercise and physical therapy, side effects may include muscle soreness or fatigue due to increased activity levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a genetic diagnosis of ARSACS or SPG7.

Select...

I can stand and move from one place to another on my own.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 consecutives days, 2 times

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 consecutives days, 2 times

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 consecutives days, 2 times for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Severity of ataxia

Secondary study objectives

Activities of Daily Living

Anxiety and Depression

Ataxia impact scale

+33 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention groupExperimental Treatment1 Intervention

The intervention group will follow a 12-week rehabilitation program, 3 times a week (two sessions in a therapy room and one session of aquatherapy).

Group II: Control groupActive Control1 Intervention

The control group will receive their usual care and will be asked to continue their usual activities and exercises for the whole project duration. Only one clinical guide exists for ataxia interventions and no specific guidelines for physiotherapy and occupational therapy interventions are specified in this guide in terms of frequency, duration and type of interventions that are effective with this population. Patients generally have an annual follow-up with a doctor or a clinical nurse at a Neuromuscular Diseases Clinic. Patients are then referred if needed for follow-up with the physiotherapist and occupational therapist. Typically, patients are referred to physiotherapy for mobility-related needs such as the introduction of a walking aid, orthotic and sometimes teaching an exercise program. In occupational therapy, patients are referred for needs such as the introduction of technical aids, home adaptation or the introduction of a wheelchair.

0 / 2Eligibility criteria met